Clinical Trials Directory

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Lenalidomide
  • drug : Dexamethasone
  • drug : Melphalan

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

Footer Links: